# Flyte Announces World Cup Activation Strategy, Targeting Global Travel Demand Surrounding 2026 Tournament Canonical URL: https://biopharmsignal.com/news/VTAK/flyte-announces-world-cup-activation-strategy-targeting-global-travel-demand-sur-01636dd5 Ticker: VTAK Company: Catheter Precision Source: Catheter Precision Published: 2026-06-09 12:00 EST ## Summary Company Positions Platform to Capture High-Value Regional Travel Demand and Build Brand Exposure during Largest Global Sporting Event Northeast Corridor... ## Article Body Company Positions Platform to Capture High-Value Regional Travel Demand and Build Brand Exposure during Largest Global Sporting Event Northeast Corridor Routes Aligned with Key U.S. Host Markets to Drive Customer Acquisition, Conversion, and Repeat Usage FORT MILL, S.C., June 09, 2026 (GLOBE NEWSWIRE) -- Flyte, a regional air mobility company focused on making private aviation more accessible and flexible for modern travelers, today announced its strategic activation plan surrounding the 2026 FIFA World Cup, positioning the Company to capture high-value regional travel demand and expand brand visibility during the largest global sporting event. The tournament, hosted across the United States, Canada, and Mexico, is expected to drive unprecedented travel volume, with millions of domestic and international visitors moving between host cities and regional markets over a six-week period. “The World Cup represents one of the largest global travel events, with constant movement of premium travelers across multiple markets,” said Marc Sellouk, CEO of Flyte. “Our model is designed to capture short-haul, time-sensitive demand, where speed, convenience, and flexibility drive customer decisions.” Targeted Demand Capture: Northeast corridor focus Flyte is concentrating its World Cup strategy on high-density Northeast routes connected to key host markets, including: New York City (HPN / TEB) ↔ Boston (BED) New York City (HPN / TEB) ↔ Philadelphia (PNE / TTN) New York City (HPN / TEB) ↔ Washington, D.C. (IAD) High-Frequency Model: Built for continuous movement Unlike single-destination events, the World Cup creates sustained, multi-week travel demand across multiple cities. Flyte’s operating model is designed to capture this through: Rapid aircraft repositioning High-frequency short-haul service Same-day and flexible scheduling Group and premium traveler bookings Direct-to-consumer booking and conversion This structure enables Flyte to participate in a continuous travel cycle rather than a single-event demand spike. About Flyte Flyte is a technology-enabled regional air mobility subsidiary of Catheter Precision, Inc. operating a growing fleet of Cirrus Vision Jets. Focused on short-haul markets, Flyte provides a faster and more efficient alternative to traditional private charter travel. Flight operations are conducted through Flyte’s wholly owned subsidiary, Ponderosa Air, LLC, an FAA-certified Part 135 air carrier. With active operations and ongoing fleet expansion, Flyte is building a scalable aviation platform designed to serve underserved regional markets. Flight operations are conducted through Flyte’s wholly owned subsidiary, Ponderosa Air, LLC, an FAA-certified Part 135 air carrier. With active operations and ongoing fleet expansion, Flyte is building a scalable aviation platform designed to serve underserved regional markets. For more information, visit www.flyflyte.com . About Catheter Precision Catheter Precision is an innovative U.S.-based medical device company developing advanced solutions to improve the treatment of cardiac arrhythmias. The Company focuses on bringing new technologies to market through physician collaboration and continuous product innovation. CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements regarding future plans, expectations, and projections, are forward-looking and subject to risks and uncertainties that could cause actual results to differ materially. Forward-looking statements can be identified by words such as “believe,” “anticipate,” “may,” “might,” “can,” “could,” “continue,” “depends,” “expect,” “expand,” “forecast,” “intend,” “predict,” “plan,” “rely,” “should,” “will,” “seek,” or similar expressions. These statements include, but are not limited to, expectations regarding growth, utilization, market share, customer behavior, and expansion initiatives. These and other risks are detailed in the Company’s filings with the Securities and Exchange Commission, including its most recent Forms 10-K and 10-Q. The Company undertakes no obligation to update any forward-looking statements except as required by law. CONTACTS Investor Relations 973-691-2000 IR@catheterprecision.com Media Relations Flyte@elev8newmedia.com ## Recent Company News - 2026-07-27 12:00 EST — [FLYTE Partners with 319 Golf Society and Named Exclusive Private Aviation Partner](https://biopharmsignal.com/news/VTAK/flyte-partners-with-319-golf-society-and-named-exclusive-private-aviation-partne-c5cad797) — Source: Catheter Precision - 2026-07-21 20:15 EST — [Flyte Partners with Blade to Expand Vision Jet Distribution](https://biopharmsignal.com/news/VTAK/flyte-partners-with-blade-to-expand-vision-jet-distribution-aaf3caf3) — Source: Catheter Precision - 2026-07-15 12:00 EST — [VTAK Announces Preliminary Second Quarter Record Revenue in Excess of $1 million](https://biopharmsignal.com/news/VTAK/vtak-announces-preliminary-second-quarter-record-revenue-in-excess-of-1-million-02ab1666) — Source: Catheter Precision - 2026-07-07 20:15 EST — [Flyte Partners with LifeVac to Equip Every Vision Jet with Life-Saving Equipment](https://biopharmsignal.com/news/VTAK/flyte-partners-with-lifevac-to-equip-every-vision-jet-with-life-saving-equipment-c5bba138) — Source: Catheter Precision - 2026-07-06 12:00 EST — [Catheter Precision, Inc. Announces Issuance of Two Key Patents](https://biopharmsignal.com/news/VTAK/catheter-precision-inc-announces-issuance-of-two-key-patents-119649de) — Source: Catheter Precision ## Related News - 2026-07-29 20:05 EST — SERA — [SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF SECOND QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON AUGUST 12, 2026](https://biopharmsignal.com/news/SERA/sera-prognostics-announces-conference-call-and-webcast-of-second-quarter-fiscal--2a2c0c5a) - 2026-07-29 20:05 EST — VKTX — [Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/VKTX/viking-therapeutics-reports-second-quarter-2026-financial-results-and-provides-c-2f09b8ce) - 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9) - 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627) - 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)